Inventor
Ryan Hudson
Inventor
San Jose, CA, US
Overview
Patents· 41 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Pprimary
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations28%
C07DHeterocyclic compounds27%
A61KPreparations for medical, dental or toiletry purposes17%
C07CAcyclic or carbocyclic compounds9%
C07BGeneral methods of organic chemistry6%
G06QInformation and communication technology [ict] specially adapted for administrative, commercial, financial, managerial or supervisory purposes5%
Y02PClimate change mitigation technologies in the production or processing of goods3%
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium2%
C07HSugars2%
C07KPeptides2%
PatentTitleYear
11,110,095Pyrimidine compounds as JAK kinase inhibitors202110,870,652Compounds and methods for modulating bruton's tyrosine kinase202010,774,080Pyrimidine compound as JAK kinase inhibitor202010,745,429Phospholidines that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer202010,745,405Glucuronide prodrugs of Janus kinase inhibitors202010,738,042Phosphonamidates that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer202010,726,437Systems and methods for interfacing with a website to modify content202010,717,722Acyl sulfonamides that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer202010,719,843Systems and methods for interfacing with a website to modify content202010,703,745Acyl phosphonamidates and acyl benzylamines that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer202010,689,416Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer202010,685,368Systems and methods for interfacing with a website to modify content202010,679,233Systems and methods for interfacing with a website to modify content202010,614,476Systems and methods for interfacing with a website to modify content202010,562,894Pyrimidine compound as JAK kinase inhibitor202010,519,197Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer201910,435,428Prodrugs of a JAK inhibitor compound for treatment of gastrointestinal inflammatory disease201910,308,646Pyrimidine compound as JAK kinase inhibitor201910,140,625Systems and methods for interfacing with a website to modify content201810,028,960Pyrimidine compounds as JAK kinase inhibitors20189,873,696Neprilysin inhibitors20189,725,470'Substituted naphthyridines as JAK kinase inhibitors'20179,555,041'Neprilysin inhibitors'20179,198,899'Dual-acting benzoimidazole antihypertensive agents'20159,181,206'Dual-acting oxazole antihypertensive agents'20159,120,758'Neprilysin inhibitors'20158,822,522'Dual-acting pyrazole antihypertensive agents'20148,735,625'Dual-acting antihypertensive agents'20148,637,676'Dual-acting benzoimidazole antihypertensive agents'20148,598,170'Dual-acting oxazole antihypertensive agents'20138,563,512'Neprilysin inhibitors'20138,394,846'Dual-acting antihypertensive agents'20138,372,984'Dual-acting oxazole antihypertensive agents'20138,350,027'Dual-acting pyrazole antihypertensive agents'20138,236,839'Dual-acting antihypertensive agents'20128,143,298'Dual-acting antihypertensive agents'20128,119,634'Dual-acting pyrazole antihypertensive agents'20128,106,082'Dual-acting antihypertensive agents'20127,956,054'Dual-acting pyrazole antihypertensive agents'20117,834,041'Dual-acting antihypertensive agents'20107,777,077'Dual-acting antihypertensive agents'2010Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2010–2014Patents assigned to THERAVANCE INC (14)· patent assignee history
2010–2014Based in Sunnyvale, CA, US· patent location history
2011–2021Based in San Jose, CA, US· patent location history
2012–2017Patents assigned to HUDSON RYAN (16)· patent assignee history
2012–2015Patents assigned to FATHEREE PAUL R (13)· patent assignee history
2012–2015Patents assigned to MCKINNELL ROBERT MURRAY (13)· patent assignee history
2015–2021Patents assigned to THERAVANCE BIOPHARMA R&D IP LLC (11)· patent assignee history
2018–2020Based in Los Angeles, CA, US· patent location history
2019–2020Based in Brisbane, CA, US· patent location history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| HUDSON RYANself | 16 | 2012–2017 |
| THERAVANCE INC | 14 | 2010–2014 |
| FATHEREE PAUL R | 13 | 2012–2015 |
| MCKINNELL ROBERT MURRAY | 13 | 2012–2015 |
| THERAVANCE BIOPHARMA R&D IP LLC | 11 | 2015–2021 |
Locations
| Location | Patents | Span |
|---|---|---|
| San Jose, California, US | 26 | 2011–2021 |
| Brisbane, California, US | 6 | 2019–2020 |
| Los Angeles, California, US | 6 | 2018–2020 |
| Sunnyvale, California, US | 3 | 2010–2014 |